Catalyst

Slingshot members are tracking this event:

PUDFA date for KEYTRUDA in treating Relapsed or Refractory Classical Hodgkin Lymphoma set on March 15 2017

Source Link:
http://www.mercknewsroom.com/news-release/oncology-newsroom/fda-grants-priority-review-supplemental-biologics-license-application

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MRK Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Mar 14, 2017
Occurred Source:
http://www.mrknewsroom.com/news-release/corporate-news/fda-approves-mercks-keytruda-pembrolizumab-adult-and-pediatric-patients-
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Keytruda, Hodgkin Lymphoma
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.